Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Proteolysis-targeting chimeras | 4 |
Molecular glue | 1 |
Target |
Mechanism BRD9 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BRAF inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EGFR exon 21 L858R mutation inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Dec 2022 |
Sponsor / Collaborator |
Start Date25 Mar 2022 |
Sponsor / Collaborator |
Start Date27 Apr 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CFT-1946 ( BRAF ) | Non-Small Cell Lung Cancer More | Phase 2 Clinical |
CFT-8634 ( BRD9 ) | Synovial Sarcoma More | Phase 2 Clinical |
CFT-7455 ( IKZF1 x IKZF3 ) | Multiple Myeloma More | Phase 2 |
CFT-8919 ( EGFR L858R ) | Non-Small Cell Lung Cancer More | IND Approval |
CFT-2718 ( BRD4 ) | Pancreatic Cancer More | Preclinical |